
Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk
Feb 14, 2024 - 00:11:56
Radio and PodcastLive Radio & Podcasts
This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabe...